drugset / Trial / NCT04217993
Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib. The experiment is divided into two parts: dose exploration and extended research.
Timeline
- Start
- 2020-01-07
- Primary completion
- 2022-08-03
- Completion
- 2022-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Jaktinib | Unknown | 100 mg | Oral |
| Subject | Jaktinib | Unknown | 150 mg | Oral |
| Subject | Jaktinib | Unknown | 200 mg | Oral |